在IBD男性血清丸激素度的分布和与炎症性肠病活动的关联
Ciaran Judge1, Daniel Lightowler1,2, Abhey Singh1
1Department of Gastroenterology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Inflammatory bowel diseases
|August 7, 2024
概括
患有炎症性肠病 (IBD) 的男性的水平与疾病活动没有独立联系. 建议对性功能障碍进行查,特别是对于那些疾病持续时间较长的人.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 男人的健康 男人的健康
背景情况:
- 在非IBD条件下,炎症和丸激素水平有相反的关系.
- 这种关系在患有炎症性肠病 (IBD) 的男性中尚未得到充分研究.
研究的目的:
- 为了确定男性IBD患者的丸激素度分布.
- 调查丸激素水平与IBD疾病活动之间的关联.
主要方法:
- 一项针对85名男性IBD患者进行的前性横截面研究.
- 收集的数据包括人口统计,疾病特征,激素水平,炎症标志物和患者报告的结果.
- 统计分析使用单变量和多变量线性回归.
主要成果:
- 平均丸激素为15.4 ± 5.2 nmol/L;17.6%的人丸激素<10.4 nmol/L.
- 活跃疾病与较低的丸激素 (P=.02) 有单变量关联,但在多变量分析中没有 (P=.06).
- 水平与性激素结合型环球蛋白相关,年龄较小.
结论:
- 在IBD男性下降的丸激素可能会被其他因素混,而不仅仅是疾病活动.
- 建议在IBD的男性中增加性功能障碍的意识和查,特别是那些疾病持续时间较长的男性.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
Inflammatory Bowel Disease II: Crohn's Disease
206
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
206
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Chronic Bowel Disorders: Introduction
436
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
436


